Skip to content
OpenCapital
Get started

Bioventus BVS U.S. Segment — Adjusted research and development expense

Similar metrics at other companies

Open Text logo
OTEXReportable Segment — Adjusted research and development
$168.38M-12.6%
Pacira BioSciences, Inc. logo
PCRXReportable Segment — Adjusted research and development
$25.36M+9.8%
Cloudflare, Inc. logo
NETReportable Segment — Research And Development Expense, Adjusted
$101.47M+32.1%
Remitly Global, Inc. logo
RELYReportable segment — Research and Development Expense, Adjusted
$62.45M+18.7%
Paylocity logo
PCTYReportable Segment — Research and Development Expense, Adjusted
$44.98M+8.1%
Five9 logo
FIVNReportable Segment — Research and Development Expense, Adjusted
$29.65M-4.6%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×—
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept bvs:ResearchAndDevelopmentExpenseAdjusted.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's u.s. segment — adjusted research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's U.S. segment — adjusted research and development expense?
Bioventus (BVS) reported U.S. segment — adjusted research and development expense of $2.29M in Q1 2026.
How has Bioventus's U.S. segment — adjusted research and development expense changed year-over-year?
Bioventus's U.S. segment — adjusted research and development expense decreased by 19.0% year-over-year, from $2.83M to $2.29M.
What is the long-term trend for Bioventus's U.S. segment — adjusted research and development expense?
Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted research and development expense has grown at a -15.0% compound annual growth rate (CAGR), from $18.33M to $11.27M.
What does U.S. segment — adjusted research and development expense mean?
This metric quantifies the adjusted investment in innovation, clinical trials, and product development specifically allocated to the U.S. market. It reflects the company's commitment to advancing its portfolio of clinically differentiated orthopedic treatments.